![Emmanuel Dulac](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Emmanuel Dulac
No open positions remaining
Profile
Emmanuel Dulac worked at Sanofi as Associate Director from 1994 to 2003.
From 2006 to 2014, worked at Novartis AG as Vice President-Global Head Lung & Cystic Fibrosis.
From 2014 to 2016, worked at Shire Plc as SVP-Global Head Rare Disease Business Unit.
From 2019 to 2022, worked at Zealand Pharma A as President & Chief Executive Officer.
From 2023 to 2024, worked at Igyxos SA as Chief Executive Officer.
Also served as Independent Director at Proteostasis Therapeutics, Inc. and as Chief Commercial Officer & Senior Vice President at Alnylam Pharmaceuticals, Inc. Education includes a doctorate from Université de Paris XI Paris Sud in 1994 and an MBA from ESSEC Business School in 1996.
Former positions of Emmanuel Dulac
| Companies | Position | End |
|---|---|---|
Igyxos SA
 Igyxos SA Pharmaceuticals: MajorHealth Technology Develops new pharmaceuticals and medical technologies in the field of human fertility | Chief Executive Officer | 2024-06-30 |
| ZEALAND PHARMA A/S | Chief Executive Officer | 2022-03-29 |
| SHIRE | Corporate Officer/Principal | 2016-07-31 |
| NOVARTIS AG | Corporate Officer/Principal | 2014-04-30 |
| SANOFI | Corporate Officer/Principal | 2003-07-31 |
Training of Emmanuel Dulac
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
86
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Zealand Pharma A/S
 Zealand Pharma A/S BiotechnologyHealth Technology Operates as a biotechnology company that discovers and develops peptide based medicines | Health Technology |
Université de Paris XI Paris Sud
 Université de Paris XI Paris Sud Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ESSEC Business School
 ESSEC Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Develops disease-modifying therapeutics for orphan and neurodegenerative diseases | Health Technology |
Igyxos SA
Igyxos SA Pharmaceuticals: MajorHealth Technology Develops new pharmaceuticals and medical technologies in the field of human fertility | Health Technology |
- Stock Market
- Insiders
- Emmanuel Dulac
